arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ABEONA THERAPEUTICS INC.

ABEO
$5.45 ▼ -0.08 (-1.36%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
64
Health
Fair
Bullish
auto_awesome

Analytical Summary

ABEONA THERAPEUTICS INC. shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $310.9M
Dividend Yield —
Revenue Growth 2745.0%
Op. Margin -120.0% ↗
ROIC -9.5% ↗
FCF / Share $-0.32 ↗
Trailing P/E —
Price / Book 2.4x
FCF Yield —
Debt / Equity 0.12
info Valuation on last close. End-of-day price, Sep 24, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$11.38M
↑ +2745.0% —
Net Income Profit after all expenses
$-20.19M
↓ -18.2% —
Operating Margin Operating profit as % of sales
-120.0%
↑ +54.6% —
FCF / Share Free cash flow per share
$-0.32
↑ +14.0% —
Long-Term Debt Long-term obligations
$14.99M
↓ -17.1% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
96
Financial Health →
51
Cash Quality
9

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 17 years · 67 quarters